nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—PTGS2—bone cancer	0.513	1	CbGaD
Thalidomide—FGFR2—skull—bone cancer	0.00308	0.23	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—bone cancer	0.00243	0.347	CrCbGaD
Thalidomide—Pomalidomide—CYP3A4—bone cancer	0.0023	0.33	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—bone cancer	0.00226	0.323	CrCbGaD
Thalidomide—PTGS2—periosteum—bone cancer	0.00114	0.0849	CbGeAlD
Thalidomide—PTGS2—leg—bone cancer	0.000909	0.0677	CbGeAlD
Thalidomide—NFKB1—connective tissue—bone cancer	0.000871	0.0649	CbGeAlD
Thalidomide—PTGS2—hindlimb—bone cancer	0.000812	0.0605	CbGeAlD
Thalidomide—PTGS2—cartilage tissue—bone cancer	0.000799	0.0595	CbGeAlD
Thalidomide—PTGS2—appendage—bone cancer	0.000696	0.0519	CbGeAlD
Thalidomide—FGFR2—connective tissue—bone cancer	0.000654	0.0487	CbGeAlD
Thalidomide—NFKB1—tendon—bone cancer	0.000598	0.0446	CbGeAlD
Thalidomide—NFKB1—bone marrow—bone cancer	0.00058	0.0432	CbGeAlD
Thalidomide—CRBN—tendon—bone cancer	0.000502	0.0374	CbGeAlD
Thalidomide—CRBN—bone marrow—bone cancer	0.000486	0.0362	CbGeAlD
Thalidomide—CRBN—spinal cord—bone cancer	0.000484	0.036	CbGeAlD
Thalidomide—FGFR2—spinal cord—bone cancer	0.000433	0.0323	CbGeAlD
Thalidomide—PTGS1—connective tissue—bone cancer	0.000208	0.0155	CbGeAlD
Thalidomide—PTGS2—connective tissue—bone cancer	0.000199	0.0148	CbGeAlD
Thalidomide—Agranulocytosis—Epirubicin—bone cancer	0.000186	0.000654	CcSEcCtD
Thalidomide—Pneumonia—Doxorubicin—bone cancer	0.000185	0.000652	CcSEcCtD
Thalidomide—Infestation—Doxorubicin—bone cancer	0.000184	0.000648	CcSEcCtD
Thalidomide—Drowsiness—Doxorubicin—bone cancer	0.000184	0.000648	CcSEcCtD
Thalidomide—Infestation NOS—Doxorubicin—bone cancer	0.000184	0.000648	CcSEcCtD
Thalidomide—Visual impairment—Methotrexate—bone cancer	0.000184	0.000648	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000183	0.000643	CcSEcCtD
Thalidomide—Hypersensitivity—Cisplatin—bone cancer	0.000182	0.000641	CcSEcCtD
Thalidomide—Bradycardia—Epirubicin—bone cancer	0.000182	0.00064	CcSEcCtD
Thalidomide—Renal failure—Doxorubicin—bone cancer	0.000181	0.000637	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—bone cancer	0.000181	0.000636	CcSEcCtD
Thalidomide—Neuropathy peripheral—Doxorubicin—bone cancer	0.000181	0.000636	CcSEcCtD
Thalidomide—Stomatitis—Doxorubicin—bone cancer	0.00018	0.000632	CcSEcCtD
Thalidomide—Rhinitis—Epirubicin—bone cancer	0.000179	0.000631	CcSEcCtD
Thalidomide—Conjunctivitis—Doxorubicin—bone cancer	0.000179	0.00063	CcSEcCtD
Thalidomide—Hepatitis—Epirubicin—bone cancer	0.000179	0.000629	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—bone cancer	0.000179	0.000628	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—bone cancer	0.000178	0.000627	CcSEcCtD
Thalidomide—Hypoaesthesia—Epirubicin—bone cancer	0.000178	0.000626	CcSEcCtD
Thalidomide—Asthenia—Cisplatin—bone cancer	0.000178	0.000624	CcSEcCtD
Thalidomide—Pharyngitis—Epirubicin—bone cancer	0.000178	0.000624	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—bone cancer	0.000177	0.000624	CcSEcCtD
Thalidomide—Sweating—Doxorubicin—bone cancer	0.000177	0.000622	CcSEcCtD
Thalidomide—Urinary tract disorder—Epirubicin—bone cancer	0.000177	0.000621	CcSEcCtD
Thalidomide—Oedema peripheral—Epirubicin—bone cancer	0.000176	0.00062	CcSEcCtD
Thalidomide—Haematuria—Doxorubicin—bone cancer	0.000176	0.000618	CcSEcCtD
Thalidomide—Urethral disorder—Epirubicin—bone cancer	0.000175	0.000617	CcSEcCtD
Thalidomide—Epistaxis—Doxorubicin—bone cancer	0.000174	0.000612	CcSEcCtD
Thalidomide—Angiopathy—Methotrexate—bone cancer	0.000173	0.00061	CcSEcCtD
Thalidomide—Sinusitis—Doxorubicin—bone cancer	0.000173	0.000608	CcSEcCtD
Thalidomide—Immune system disorder—Methotrexate—bone cancer	0.000173	0.000607	CcSEcCtD
Thalidomide—Visual impairment—Epirubicin—bone cancer	0.000172	0.000606	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—bone cancer	0.000172	0.000606	CcSEcCtD
Thalidomide—Agranulocytosis—Doxorubicin—bone cancer	0.000172	0.000605	CcSEcCtD
Thalidomide—Chills—Methotrexate—bone cancer	0.000172	0.000603	CcSEcCtD
Thalidomide—Diarrhoea—Cisplatin—bone cancer	0.000169	0.000595	CcSEcCtD
Thalidomide—Erythema multiforme—Epirubicin—bone cancer	0.000169	0.000595	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—bone cancer	0.000169	0.000594	CcSEcCtD
Thalidomide—Bradycardia—Doxorubicin—bone cancer	0.000169	0.000593	CcSEcCtD
Thalidomide—Mental disorder—Methotrexate—bone cancer	0.000167	0.000589	CcSEcCtD
Thalidomide—Eye disorder—Epirubicin—bone cancer	0.000167	0.000588	CcSEcCtD
Thalidomide—Tinnitus—Epirubicin—bone cancer	0.000167	0.000586	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—bone cancer	0.000166	0.000585	CcSEcCtD
Thalidomide—Cardiac disorder—Epirubicin—bone cancer	0.000166	0.000584	CcSEcCtD
Thalidomide—Rhinitis—Doxorubicin—bone cancer	0.000166	0.000583	CcSEcCtD
Thalidomide—Hepatitis—Doxorubicin—bone cancer	0.000166	0.000582	CcSEcCtD
Thalidomide—Hypoaesthesia—Doxorubicin—bone cancer	0.000165	0.000579	CcSEcCtD
Thalidomide—Pharyngitis—Doxorubicin—bone cancer	0.000164	0.000578	CcSEcCtD
Thalidomide—Urinary tract disorder—Doxorubicin—bone cancer	0.000163	0.000575	CcSEcCtD
Thalidomide—Oedema peripheral—Doxorubicin—bone cancer	0.000163	0.000573	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—bone cancer	0.000163	0.000573	CcSEcCtD
Thalidomide—Angiopathy—Epirubicin—bone cancer	0.000162	0.000571	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—bone cancer	0.000162	0.000571	CcSEcCtD
Thalidomide—Immune system disorder—Epirubicin—bone cancer	0.000162	0.000568	CcSEcCtD
Thalidomide—Mediastinal disorder—Epirubicin—bone cancer	0.000161	0.000567	CcSEcCtD
Thalidomide—Back pain—Methotrexate—bone cancer	0.000161	0.000566	CcSEcCtD
Thalidomide—Chills—Epirubicin—bone cancer	0.000161	0.000564	CcSEcCtD
Thalidomide—Arrhythmia—Epirubicin—bone cancer	0.00016	0.000562	CcSEcCtD
Thalidomide—Visual impairment—Doxorubicin—bone cancer	0.00016	0.000561	CcSEcCtD
Thalidomide—Alopecia—Epirubicin—bone cancer	0.000158	0.000556	CcSEcCtD
Thalidomide—Vomiting—Cisplatin—bone cancer	0.000157	0.000553	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—bone cancer	0.000157	0.000551	CcSEcCtD
Thalidomide—Mental disorder—Epirubicin—bone cancer	0.000157	0.000551	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—bone cancer	0.000157	0.00055	CcSEcCtD
Thalidomide—Rash—Cisplatin—bone cancer	0.000156	0.000549	CcSEcCtD
Thalidomide—Dermatitis—Cisplatin—bone cancer	0.000156	0.000548	CcSEcCtD
Thalidomide—Malnutrition—Epirubicin—bone cancer	0.000156	0.000548	CcSEcCtD
Thalidomide—Eye disorder—Doxorubicin—bone cancer	0.000155	0.000544	CcSEcCtD
Thalidomide—Ill-defined disorder—Methotrexate—bone cancer	0.000154	0.000543	CcSEcCtD
Thalidomide—Tinnitus—Doxorubicin—bone cancer	0.000154	0.000543	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—bone cancer	0.000154	0.000541	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—bone cancer	0.000154	0.00054	CcSEcCtD
Thalidomide—Flatulence—Epirubicin—bone cancer	0.000153	0.00054	CcSEcCtD
Thalidomide—Tension—Epirubicin—bone cancer	0.000153	0.000537	CcSEcCtD
Thalidomide—Dysgeusia—Epirubicin—bone cancer	0.000153	0.000536	CcSEcCtD
Thalidomide—Nervousness—Epirubicin—bone cancer	0.000151	0.000532	CcSEcCtD
Thalidomide—Back pain—Epirubicin—bone cancer	0.000151	0.00053	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—bone cancer	0.00015	0.000528	CcSEcCtD
Thalidomide—Malaise—Methotrexate—bone cancer	0.00015	0.000528	CcSEcCtD
Thalidomide—Muscle spasms—Epirubicin—bone cancer	0.00015	0.000526	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—bone cancer	0.00015	0.000526	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—bone cancer	0.00015	0.000526	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—bone cancer	0.000149	0.000525	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—bone cancer	0.000149	0.000524	CcSEcCtD
Thalidomide—Chills—Doxorubicin—bone cancer	0.000149	0.000522	CcSEcCtD
Thalidomide—CYP2E1—tendon—bone cancer	0.000148	0.011	CbGeAlD
Thalidomide—Arrhythmia—Doxorubicin—bone cancer	0.000148	0.00052	CcSEcCtD
Thalidomide—Nausea—Cisplatin—bone cancer	0.000147	0.000517	CcSEcCtD
Thalidomide—Vision blurred—Epirubicin—bone cancer	0.000147	0.000516	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—bone cancer	0.000146	0.000514	CcSEcCtD
Thalidomide—Cough—Methotrexate—bone cancer	0.000145	0.000511	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—bone cancer	0.000145	0.00051	CcSEcCtD
Thalidomide—Ill-defined disorder—Epirubicin—bone cancer	0.000145	0.000508	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—bone cancer	0.000144	0.000507	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—bone cancer	0.000144	0.000507	CcSEcCtD
Thalidomide—Anaemia—Epirubicin—bone cancer	0.000144	0.000506	CcSEcCtD
Thalidomide—Agitation—Epirubicin—bone cancer	0.000143	0.000503	CcSEcCtD
Thalidomide—CYP2E1—spinal cord—bone cancer	0.000143	0.0107	CbGeAlD
Thalidomide—PTGS1—tendon—bone cancer	0.000143	0.0106	CbGeAlD
Thalidomide—Flatulence—Doxorubicin—bone cancer	0.000142	0.000499	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—bone cancer	0.000142	0.000498	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—bone cancer	0.000142	0.000498	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—bone cancer	0.000142	0.000498	CcSEcCtD
Thalidomide—Tension—Doxorubicin—bone cancer	0.000141	0.000497	CcSEcCtD
Thalidomide—Dysgeusia—Doxorubicin—bone cancer	0.000141	0.000496	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000141	0.000495	CcSEcCtD
Thalidomide—Malaise—Epirubicin—bone cancer	0.00014	0.000494	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—bone cancer	0.00014	0.000492	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—bone cancer	0.00014	0.000492	CcSEcCtD
Thalidomide—Vertigo—Epirubicin—bone cancer	0.00014	0.000492	CcSEcCtD
Thalidomide—Syncope—Epirubicin—bone cancer	0.00014	0.000491	CcSEcCtD
Thalidomide—Leukopenia—Epirubicin—bone cancer	0.000139	0.00049	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—bone cancer	0.000139	0.00049	CcSEcCtD
Thalidomide—Muscle spasms—Doxorubicin—bone cancer	0.000139	0.000487	CcSEcCtD
Thalidomide—PTGS1—spinal cord—bone cancer	0.000138	0.0103	CbGeAlD
Thalidomide—Palpitations—Epirubicin—bone cancer	0.000138	0.000484	CcSEcCtD
Thalidomide—Confusional state—Methotrexate—bone cancer	0.000137	0.000482	CcSEcCtD
Thalidomide—Loss of consciousness—Epirubicin—bone cancer	0.000137	0.000481	CcSEcCtD
Thalidomide—PTGS2—tendon—bone cancer	0.000137	0.0102	CbGeAlD
Thalidomide—Cough—Epirubicin—bone cancer	0.000136	0.000478	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—bone cancer	0.000136	0.000477	CcSEcCtD
Thalidomide—Convulsion—Epirubicin—bone cancer	0.000135	0.000474	CcSEcCtD
Thalidomide—Infection—Methotrexate—bone cancer	0.000135	0.000474	CcSEcCtD
Thalidomide—Hypertension—Epirubicin—bone cancer	0.000134	0.000473	CcSEcCtD
Thalidomide—Ill-defined disorder—Doxorubicin—bone cancer	0.000134	0.00047	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—bone cancer	0.000133	0.000468	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—bone cancer	0.000133	0.000468	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—bone cancer	0.000133	0.000468	CcSEcCtD
Thalidomide—Chest pain—Epirubicin—bone cancer	0.000133	0.000466	CcSEcCtD
Thalidomide—Arthralgia—Epirubicin—bone cancer	0.000133	0.000466	CcSEcCtD
Thalidomide—Myalgia—Epirubicin—bone cancer	0.000133	0.000466	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—bone cancer	0.000132	0.000466	CcSEcCtD
Thalidomide—PTGS2—bone marrow—bone cancer	0.000132	0.00985	CbGeAlD
Thalidomide—Anxiety—Epirubicin—bone cancer	0.000132	0.000465	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—bone cancer	0.000132	0.000464	CcSEcCtD
Thalidomide—PTGS2—spinal cord—bone cancer	0.000132	0.00981	CbGeAlD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000132	0.000463	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—bone cancer	0.000131	0.000462	CcSEcCtD
Thalidomide—Discomfort—Epirubicin—bone cancer	0.000131	0.000461	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—bone cancer	0.00013	0.000457	CcSEcCtD
Thalidomide—Dry mouth—Epirubicin—bone cancer	0.00013	0.000456	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—bone cancer	0.000129	0.000455	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—bone cancer	0.000129	0.000455	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—bone cancer	0.000129	0.000454	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—bone cancer	0.000129	0.000454	CcSEcCtD
Thalidomide—Confusional state—Epirubicin—bone cancer	0.000128	0.000451	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—bone cancer	0.000127	0.000448	CcSEcCtD
Thalidomide—Oedema—Epirubicin—bone cancer	0.000127	0.000447	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—bone cancer	0.000127	0.000446	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—bone cancer	0.000127	0.000445	CcSEcCtD
Thalidomide—Infection—Epirubicin—bone cancer	0.000126	0.000444	CcSEcCtD
Thalidomide—Cough—Doxorubicin—bone cancer	0.000126	0.000442	CcSEcCtD
Thalidomide—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000126	0.00069	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ATF1—bone cancer	0.000125	0.00069	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—KIT—bone cancer	0.000125	0.000688	CbGpPWpGaD
Thalidomide—Shock—Epirubicin—bone cancer	0.000125	0.00044	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—bone cancer	0.000125	0.000439	CcSEcCtD
Thalidomide—Nervous system disorder—Epirubicin—bone cancer	0.000125	0.000438	CcSEcCtD
Thalidomide—Thrombocytopenia—Epirubicin—bone cancer	0.000124	0.000438	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—bone cancer	0.000124	0.000437	CcSEcCtD
Thalidomide—Tachycardia—Epirubicin—bone cancer	0.000124	0.000436	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000124	0.000435	CcSEcCtD
Thalidomide—Skin disorder—Epirubicin—bone cancer	0.000123	0.000434	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—RB1—bone cancer	0.000123	0.000678	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Epirubicin—bone cancer	0.000123	0.000432	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—bone cancer	0.000123	0.000432	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—bone cancer	0.000123	0.000431	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—bone cancer	0.000123	0.000431	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—bone cancer	0.000123	0.000431	CcSEcCtD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—TP53—bone cancer	0.000122	0.000673	CbGpPWpGaD
Thalidomide—Anxiety—Doxorubicin—bone cancer	0.000122	0.00043	CcSEcCtD
Thalidomide—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000122	0.000672	CbGpPWpGaD
Thalidomide—Paraesthesia—Methotrexate—bone cancer	0.000122	0.000429	CcSEcCtD
Thalidomide—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000122	0.00067	CbGpPWpGaD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000122	0.000428	CcSEcCtD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.000122	0.000668	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000122	0.000668	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000122	0.000668	CbGpPWpGaD
Thalidomide—Discomfort—Doxorubicin—bone cancer	0.000121	0.000426	CcSEcCtD
Thalidomide—Anorexia—Epirubicin—bone cancer	0.000121	0.000426	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—bone cancer	0.000121	0.000426	CcSEcCtD
Thalidomide—NFKB1—Cellular Senescence—JUN—bone cancer	0.000121	0.000664	CbGpPWpGaD
Thalidomide—Somnolence—Methotrexate—bone cancer	0.000121	0.000425	CcSEcCtD
Thalidomide—TNF—Alzheimers Disease—TP53—bone cancer	0.000121	0.000663	CbGpPWpGaD
Thalidomide—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000121	0.000663	CbGpPWpGaD
Thalidomide—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.00012	0.000661	CbGpPWpGaD
Thalidomide—Dry mouth—Doxorubicin—bone cancer	0.00012	0.000422	CcSEcCtD
Thalidomide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.00012	0.000658	CbGpPWpGaD
Thalidomide—Dyspepsia—Methotrexate—bone cancer	0.00012	0.00042	CcSEcCtD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	0.000119	0.000656	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ATF1—bone cancer	0.000119	0.000654	CbGpPWpGaD
Thalidomide—Hypotension—Epirubicin—bone cancer	0.000119	0.000418	CcSEcCtD
Thalidomide—FGFR2—Signaling by NGF—KIT—bone cancer	0.000119	0.000653	CbGpPWpGaD
Thalidomide—Confusional state—Doxorubicin—bone cancer	0.000119	0.000417	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000118	0.000651	CbGpPWpGaD
Thalidomide—Decreased appetite—Methotrexate—bone cancer	0.000118	0.000415	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—BRAF—bone cancer	0.000118	0.000647	CbGpPWpGaD
Thalidomide—Oedema—Doxorubicin—bone cancer	0.000118	0.000413	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000117	0.000412	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—bone cancer	0.000117	0.000412	CcSEcCtD
Thalidomide—Infection—Doxorubicin—bone cancer	0.000117	0.000411	CcSEcCtD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000117	0.000641	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—JUN—bone cancer	0.000116	0.000639	CbGpPWpGaD
Thalidomide—Pain—Methotrexate—bone cancer	0.000116	0.000408	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000116	0.000407	CcSEcCtD
Thalidomide—Shock—Doxorubicin—bone cancer	0.000116	0.000407	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—bone cancer	0.000115	0.000406	CcSEcCtD
Thalidomide—CYP1A1—Biological oxidations—GSTP1—bone cancer	0.000115	0.000633	CbGpPWpGaD
Thalidomide—Thrombocytopenia—Doxorubicin—bone cancer	0.000115	0.000405	CcSEcCtD
Thalidomide—Insomnia—Epirubicin—bone cancer	0.000115	0.000404	CcSEcCtD
Thalidomide—TNF—Apoptosis—TP53—bone cancer	0.000115	0.000631	CbGpPWpGaD
Thalidomide—Tachycardia—Doxorubicin—bone cancer	0.000115	0.000404	CcSEcCtD
Thalidomide—PTGS1—Metabolism—NDUFA12—bone cancer	0.000115	0.00063	CbGpPWpGaD
Thalidomide—Skin disorder—Doxorubicin—bone cancer	0.000114	0.000402	CcSEcCtD
Thalidomide—Paraesthesia—Epirubicin—bone cancer	0.000114	0.000401	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—bone cancer	0.000114	0.0004	CcSEcCtD
Thalidomide—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000114	0.000625	CbGpPWpGaD
Thalidomide—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000113	0.000623	CbGpPWpGaD
Thalidomide—Dyspnoea—Epirubicin—bone cancer	0.000113	0.000398	CcSEcCtD
Thalidomide—Somnolence—Epirubicin—bone cancer	0.000113	0.000397	CcSEcCtD
Thalidomide—FGFR2—Signaling by SCF-KIT—EGFR—bone cancer	0.000113	0.000619	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000112	0.000617	CbGpPWpGaD
Thalidomide—Anorexia—Doxorubicin—bone cancer	0.000112	0.000394	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—bone cancer	0.000112	0.000394	CcSEcCtD
Thalidomide—Dyspepsia—Epirubicin—bone cancer	0.000112	0.000393	CcSEcCtD
Thalidomide—FGFR2—Signaling by NGF—BRAF—bone cancer	0.000112	0.000614	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Methotrexate—bone cancer	0.000111	0.00039	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—RB1—bone cancer	0.000111	0.000608	CbGpPWpGaD
Thalidomide—Decreased appetite—Epirubicin—bone cancer	0.00011	0.000388	CcSEcCtD
Thalidomide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.00011	0.000606	CbGpPWpGaD
Thalidomide—Hypotension—Doxorubicin—bone cancer	0.00011	0.000386	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Epirubicin—bone cancer	0.00011	0.000386	CcSEcCtD
Thalidomide—Fatigue—Epirubicin—bone cancer	0.00011	0.000385	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000109	0.000601	CbGpPWpGaD
Thalidomide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000109	0.000598	CbGpPWpGaD
Thalidomide—Pain—Epirubicin—bone cancer	0.000109	0.000382	CcSEcCtD
Thalidomide—Constipation—Epirubicin—bone cancer	0.000109	0.000382	CcSEcCtD
Thalidomide—Urticaria—Methotrexate—bone cancer	0.000108	0.000379	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—EGFR—bone cancer	0.000108	0.000592	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000108	0.000592	CbGpPWpGaD
Thalidomide—Body temperature increased—Methotrexate—bone cancer	0.000107	0.000377	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—bone cancer	0.000107	0.000377	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000107	0.000377	CcSEcCtD
Thalidomide—Insomnia—Doxorubicin—bone cancer	0.000106	0.000374	CcSEcCtD
Thalidomide—TNF—SIDS Susceptibility Pathways—JUN—bone cancer	0.000106	0.000583	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—EGFR—bone cancer	0.000106	0.000583	CbGpPWpGaD
Thalidomide—Paraesthesia—Doxorubicin—bone cancer	0.000106	0.000371	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—MDM2—bone cancer	0.000105	0.000578	CbGpPWpGaD
Thalidomide—Dyspnoea—Doxorubicin—bone cancer	0.000105	0.000369	CcSEcCtD
Thalidomide—Feeling abnormal—Epirubicin—bone cancer	0.000105	0.000368	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—bone cancer	0.000105	0.000368	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—EGFR—bone cancer	0.000104	0.000573	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Epirubicin—bone cancer	0.000104	0.000365	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000104	0.00057	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	0.000104	0.000569	CbGpPWpGaD
Thalidomide—Dyspepsia—Doxorubicin—bone cancer	0.000104	0.000364	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—EGFR—bone cancer	0.000103	0.000567	CbGpPWpGaD
Thalidomide—Decreased appetite—Doxorubicin—bone cancer	0.000102	0.000359	CcSEcCtD
Thalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000102	0.000562	CbGpPWpGaD
Thalidomide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000102	0.000357	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—bone cancer	0.000101	0.000356	CcSEcCtD
Thalidomide—FGFR2—Downstream signal transduction—EGFR—bone cancer	0.000101	0.000556	CbGpPWpGaD
Thalidomide—Urticaria—Epirubicin—bone cancer	0.000101	0.000355	CcSEcCtD
Thalidomide—FGFR2—Signaling by FGFR—EGFR—bone cancer	0.000101	0.000554	CbGpPWpGaD
Thalidomide—Constipation—Doxorubicin—bone cancer	0.000101	0.000354	CcSEcCtD
Thalidomide—Pain—Doxorubicin—bone cancer	0.000101	0.000354	CcSEcCtD
Thalidomide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.0001	0.000553	CbGpPWpGaD
Thalidomide—Abdominal pain—Epirubicin—bone cancer	0.0001	0.000353	CcSEcCtD
Thalidomide—Body temperature increased—Epirubicin—bone cancer	0.0001	0.000353	CcSEcCtD
Thalidomide—FGFR2—Signaling by ERBB2—EGFR—bone cancer	0.0001	0.000551	CbGpPWpGaD
Thalidomide—Hypersensitivity—Methotrexate—bone cancer	0.0001	0.000352	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.0001	0.00055	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—JUN—bone cancer	9.99e-05	0.000549	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—EGFR—bone cancer	9.97e-05	0.000548	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	9.91e-05	0.000545	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	9.89e-05	0.000544	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—MDM2—bone cancer	9.86e-05	0.000542	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	9.85e-05	0.000542	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	9.83e-05	0.00054	CbGpPWpGaD
Thalidomide—Asthenia—Methotrexate—bone cancer	9.75e-05	0.000343	CcSEcCtD
Thalidomide—Feeling abnormal—Doxorubicin—bone cancer	9.69e-05	0.000341	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—bone cancer	9.62e-05	0.000338	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—bone cancer	9.61e-05	0.000338	CcSEcCtD
Thalidomide—PTGS1—Metabolism—NT5C3A—bone cancer	9.49e-05	0.000522	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—GSTP1—bone cancer	9.43e-05	0.000518	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TP53—bone cancer	9.43e-05	0.000518	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—EGFR—bone cancer	9.38e-05	0.000516	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	9.38e-05	0.000516	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—EGFR—bone cancer	9.38e-05	0.000516	CbGpPWpGaD
Thalidomide—Hypersensitivity—Epirubicin—bone cancer	9.37e-05	0.000329	CcSEcCtD
Thalidomide—FGFR2—Signaling by NGF—MDM2—bone cancer	9.35e-05	0.000514	CbGpPWpGaD
Thalidomide—Urticaria—Doxorubicin—bone cancer	9.34e-05	0.000328	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	9.3e-05	0.000511	CbGpPWpGaD
Thalidomide—Body temperature increased—Doxorubicin—bone cancer	9.3e-05	0.000327	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—bone cancer	9.3e-05	0.000327	CcSEcCtD
Thalidomide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	9.3e-05	0.000511	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—EGFR—bone cancer	9.3e-05	0.000511	CbGpPWpGaD
Thalidomide—Diarrhoea—Methotrexate—bone cancer	9.29e-05	0.000327	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—EGFR—bone cancer	9.21e-05	0.000507	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—EGFR—bone cancer	9.17e-05	0.000504	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—EGFR—bone cancer	9.15e-05	0.000503	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—JUN—bone cancer	9.13e-05	0.000502	CbGpPWpGaD
Thalidomide—Asthenia—Epirubicin—bone cancer	9.12e-05	0.000321	CcSEcCtD
Thalidomide—PTGS2—Metabolism—NDUFA12—bone cancer	9.1e-05	0.0005	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GRM4—bone cancer	9.09e-05	0.0005	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RGS1—bone cancer	9.09e-05	0.0005	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	9.01e-05	0.000496	CbGpPWpGaD
Thalidomide—Pruritus—Epirubicin—bone cancer	8.99e-05	0.000316	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—bone cancer	8.98e-05	0.000316	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—TP53—bone cancer	8.75e-05	0.000481	CbGpPWpGaD
Thalidomide—Diarrhoea—Epirubicin—bone cancer	8.7e-05	0.000306	CcSEcCtD
Thalidomide—FGFR2—B Cell Activation—EGFR—bone cancer	8.68e-05	0.000477	CbGpPWpGaD
Thalidomide—Hypersensitivity—Doxorubicin—bone cancer	8.67e-05	0.000305	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—bone cancer	8.65e-05	0.000476	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8.65e-05	0.000476	CbGpPWpGaD
Thalidomide—Vomiting—Methotrexate—bone cancer	8.64e-05	0.000304	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—RGS1—bone cancer	8.63e-05	0.000474	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GRM4—bone cancer	8.63e-05	0.000474	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—GSTP1—bone cancer	8.6e-05	0.000473	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—CYP3A4—bone cancer	8.59e-05	0.000472	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MET—bone cancer	8.59e-05	0.000472	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CDK4—bone cancer	8.59e-05	0.000472	CbGpPWpGaD
Thalidomide—Rash—Methotrexate—bone cancer	8.56e-05	0.000301	CcSEcCtD
Thalidomide—CYP2E1—Metabolism—NDUFA12—bone cancer	8.56e-05	0.000471	CbGpPWpGaD
Thalidomide—Dermatitis—Methotrexate—bone cancer	8.56e-05	0.000301	CcSEcCtD
Thalidomide—CYP3A5—Metabolism—NDUFA12—bone cancer	8.55e-05	0.00047	CbGpPWpGaD
Thalidomide—Headache—Methotrexate—bone cancer	8.51e-05	0.000299	CcSEcCtD
Thalidomide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	8.48e-05	0.000466	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	8.47e-05	0.000466	CbGpPWpGaD
Thalidomide—Asthenia—Doxorubicin—bone cancer	8.44e-05	0.000297	CcSEcCtD
Thalidomide—Dizziness—Epirubicin—bone cancer	8.41e-05	0.000296	CcSEcCtD
Thalidomide—Pruritus—Doxorubicin—bone cancer	8.32e-05	0.000293	CcSEcCtD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	8.31e-05	0.000457	CbGpPWpGaD
Thalidomide—Vomiting—Epirubicin—bone cancer	8.08e-05	0.000284	CcSEcCtD
Thalidomide—CYP1A1—Metabolism—NDUFA12—bone cancer	8.07e-05	0.000444	CbGpPWpGaD
Thalidomide—Nausea—Methotrexate—bone cancer	8.07e-05	0.000284	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—bone cancer	8.05e-05	0.000283	CcSEcCtD
Thalidomide—Rash—Epirubicin—bone cancer	8.01e-05	0.000282	CcSEcCtD
Thalidomide—Dermatitis—Epirubicin—bone cancer	8.01e-05	0.000282	CcSEcCtD
Thalidomide—NFKB1—Cellular Senescence—TP53—bone cancer	7.98e-05	0.000439	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MMP9—bone cancer	7.97e-05	0.000438	CbGpPWpGaD
Thalidomide—Headache—Epirubicin—bone cancer	7.96e-05	0.00028	CcSEcCtD
Thalidomide—FGFR2—Disease—ENO2—bone cancer	7.94e-05	0.000436	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GRM1—bone cancer	7.88e-05	0.000433	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—EGFR—bone cancer	7.85e-05	0.000432	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	7.81e-05	0.000429	CbGpPWpGaD
Thalidomide—Dizziness—Doxorubicin—bone cancer	7.78e-05	0.000273	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	7.75e-05	0.000426	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	7.75e-05	0.000426	CbGpPWpGaD
Thalidomide—Nausea—Epirubicin—bone cancer	7.55e-05	0.000265	CcSEcCtD
Thalidomide—PTGS2—Metabolism—NT5C3A—bone cancer	7.54e-05	0.000414	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GRM1—bone cancer	7.48e-05	0.000411	CbGpPWpGaD
Thalidomide—Vomiting—Doxorubicin—bone cancer	7.48e-05	0.000263	CcSEcCtD
Thalidomide—Rash—Doxorubicin—bone cancer	7.42e-05	0.000261	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—bone cancer	7.41e-05	0.00026	CcSEcCtD
Thalidomide—Headache—Doxorubicin—bone cancer	7.37e-05	0.000259	CcSEcCtD
Thalidomide—FGFR2—Disease—DHFR—bone cancer	7.36e-05	0.000405	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—GSTP1—bone cancer	7.34e-05	0.000404	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ATF1—bone cancer	7.3e-05	0.000402	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	7.24e-05	0.000398	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP2—bone cancer	7.16e-05	0.000394	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KIT—bone cancer	7.14e-05	0.000392	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL3—bone cancer	7.12e-05	0.000392	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NT5C3A—bone cancer	7.1e-05	0.00039	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	7.09e-05	0.00039	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NT5C3A—bone cancer	7.08e-05	0.000389	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—bone cancer	7.03e-05	0.000387	CbGpPWpGaD
Thalidomide—Nausea—Doxorubicin—bone cancer	6.99e-05	0.000246	CcSEcCtD
Thalidomide—FGFR2—Immune System—ATF1—bone cancer	6.93e-05	0.000381	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KIT—bone cancer	6.85e-05	0.000377	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KIT—bone cancer	6.77e-05	0.000372	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL3—bone cancer	6.76e-05	0.000372	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—EGFR—bone cancer	6.73e-05	0.00037	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NT5C3A—bone cancer	6.69e-05	0.000368	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NDUFA12—bone cancer	6.61e-05	0.000363	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—bone cancer	6.59e-05	0.000363	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CDK4—bone cancer	6.54e-05	0.00036	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MET—bone cancer	6.54e-05	0.00036	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KIT—bone cancer	6.5e-05	0.000358	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—EGFR—bone cancer	6.44e-05	0.000354	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.41e-05	0.000353	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—EGFR—bone cancer	6.39e-05	0.000351	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—bone cancer	6.03e-05	0.000331	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NDUFA12—bone cancer	6.02e-05	0.000331	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	5.95e-05	0.000327	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MDM2—bone cancer	5.62e-05	0.000309	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.58e-05	0.000307	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SMO—bone cancer	5.55e-05	0.000305	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NT5C3A—bone cancer	5.47e-05	0.000301	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP2—bone cancer	5.46e-05	0.0003	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—bone cancer	5.41e-05	0.000297	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—MDM2—bone cancer	5.4e-05	0.000297	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP9—bone cancer	5.38e-05	0.000296	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFBR2—bone cancer	5.34e-05	0.000293	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MDM2—bone cancer	5.33e-05	0.000293	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SMO—bone cancer	5.27e-05	0.00029	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NDUFA12—bone cancer	5.15e-05	0.000283	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—MDM2—bone cancer	5.12e-05	0.000282	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GNA11—bone cancer	5.08e-05	0.000279	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NT5C3A—bone cancer	4.99e-05	0.000274	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—JUN—bone cancer	4.89e-05	0.000269	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GNA11—bone cancer	4.82e-05	0.000265	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ATF1—bone cancer	4.72e-05	0.00026	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—JUN—bone cancer	4.64e-05	0.000255	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL3—bone cancer	4.61e-05	0.000253	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ATF1—bone cancer	4.48e-05	0.000246	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.38e-05	0.000241	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL3—bone cancer	4.37e-05	0.00024	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—bone cancer	4.35e-05	0.000239	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NT5C3A—bone cancer	4.27e-05	0.000235	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ENO2—bone cancer	4.16e-05	0.000229	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KIT—bone cancer	4.16e-05	0.000229	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—bone cancer	4.1e-05	0.000225	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KIT—bone cancer	3.94e-05	0.000217	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ENO2—bone cancer	3.94e-05	0.000217	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFBR2—bone cancer	3.94e-05	0.000217	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—DHFR—bone cancer	3.86e-05	0.000212	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—bone cancer	3.84e-05	0.000211	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFBR2—bone cancer	3.74e-05	0.000205	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1R—bone cancer	3.71e-05	0.000204	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—bone cancer	3.69e-05	0.000203	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.68e-05	0.000202	CbGpPWpGaD
Thalidomide—PTGS2—Disease—DHFR—bone cancer	3.66e-05	0.000201	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—bone cancer	3.64e-05	0.0002	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KIT—bone cancer	3.64e-05	0.0002	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GNA11—bone cancer	3.61e-05	0.000198	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1R—bone cancer	3.52e-05	0.000193	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—bone cancer	3.5e-05	0.000192	CbGpPWpGaD
Thalidomide—FGFR2—Disease—BRAF—bone cancer	3.42e-05	0.000188	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—bone cancer	3.31e-05	0.000182	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ENO2—bone cancer	3.3e-05	0.000182	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MDM2—bone cancer	3.27e-05	0.00018	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP3A4—bone cancer	3.27e-05	0.00018	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.25e-05	0.000179	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ENO2—bone cancer	3.11e-05	0.000171	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MDM2—bone cancer	3.11e-05	0.000171	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ENO2—bone cancer	3.1e-05	0.000171	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—DHFR—bone cancer	3.06e-05	0.000168	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ENO2—bone cancer	2.93e-05	0.000161	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—DHFR—bone cancer	2.88e-05	0.000159	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—DHFR—bone cancer	2.88e-05	0.000158	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MDM2—bone cancer	2.87e-05	0.000158	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GNA11—bone cancer	2.86e-05	0.000157	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—JUN—bone cancer	2.85e-05	0.000156	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTP1—bone cancer	2.8e-05	0.000154	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—bone cancer	2.76e-05	0.000152	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—DHFR—bone cancer	2.72e-05	0.000149	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—JUN—bone cancer	2.7e-05	0.000148	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GNA11—bone cancer	2.69e-05	0.000148	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GNA11—bone cancer	2.69e-05	0.000148	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KIT—bone cancer	2.69e-05	0.000148	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFBR2—bone cancer	2.65e-05	0.000146	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP3A4—bone cancer	2.6e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KIT—bone cancer	2.55e-05	0.00014	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GNA11—bone cancer	2.54e-05	0.00014	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—BRAF—bone cancer	2.53e-05	0.000139	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP3A4—bone cancer	2.44e-05	0.000134	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP3A4—bone cancer	2.44e-05	0.000134	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ENO2—bone cancer	2.4e-05	0.000132	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BRAF—bone cancer	2.4e-05	0.000132	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP3A4—bone cancer	2.3e-05	0.000127	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.29e-05	0.000126	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—bone cancer	2.24e-05	0.000123	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—DHFR—bone cancer	2.22e-05	0.000122	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTP1—bone cancer	2.22e-05	0.000122	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ENO2—bone cancer	2.19e-05	0.00012	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—bone cancer	2.12e-05	0.000117	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MDM2—bone cancer	2.12e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTP1—bone cancer	2.09e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTP1—bone cancer	2.09e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNA11—bone cancer	2.08e-05	0.000114	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DHFR—bone cancer	2.03e-05	0.000112	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MDM2—bone cancer	2.01e-05	0.00011	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTP1—bone cancer	1.97e-05	0.000108	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—bone cancer	1.96e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNA11—bone cancer	1.9e-05	0.000104	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP3A4—bone cancer	1.88e-05	0.000104	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.88e-05	0.000103	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO2—bone cancer	1.87e-05	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JUN—bone cancer	1.84e-05	0.000101	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KIT—bone cancer	1.81e-05	9.94e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—bone cancer	1.79e-05	9.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JUN—bone cancer	1.75e-05	9.6e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DHFR—bone cancer	1.73e-05	9.53e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP3A4—bone cancer	1.72e-05	9.45e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.71e-05	9.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BRAF—bone cancer	1.7e-05	9.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—bone cancer	1.7e-05	9.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNA11—bone cancer	1.62e-05	8.91e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—bone cancer	1.61e-05	8.86e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—bone cancer	1.47e-05	8.08e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP3A4—bone cancer	1.47e-05	8.07e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.46e-05	8.03e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—bone cancer	1.45e-05	7.96e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—bone cancer	1.45e-05	7.95e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MDM2—bone cancer	1.42e-05	7.83e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—bone cancer	1.37e-05	7.55e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—bone cancer	1.26e-05	6.91e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—bone cancer	1.21e-05	6.68e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—bone cancer	1.15e-05	6.34e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—bone cancer	1.08e-05	5.95e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—bone cancer	1.08e-05	5.94e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—bone cancer	1.02e-05	5.61e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—bone cancer	9.73e-06	5.35e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—bone cancer	8.35e-06	4.59e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—bone cancer	7.62e-06	4.19e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—bone cancer	6.51e-06	3.58e-05	CbGpPWpGaD
